1887

Abstract

The serotypes and molecular clones of penicillin-nonsusceptible (PNSP) responsible for invasive pneumococcal disease (IPD) and discharging ears in metropolitan New South Wales were characterized to form a baseline prior to introduction of the heptavalent conjugate pneumococcal vaccine in Australia. Pneumococci isolated between 1 July 2000 and 30 June 2003 in Sydney from children <15 years were tested for antibiotic susceptibilities and serotyped. Penicillin-nonsusceptible pneumococci were typed by multilocus sequence typing and BOX PCR. During this period, 97 (13.9 %) of 698 pneumococci from IPD that were serotyped were penicillin-nonsusceptible. Of 607 pneumococci from discharging ears, 157 (26.1 %) were penicillin-nonsusceptible. Serotype 14 was the predominant serotype responsible for IPD and serotype 19F predominated from discharging ears. The heptavalent vaccine serotypes accounted for 613 (87.8 %) of all invasive isolates and 420 (69.8 %) of all isolates from discharging ears. Representatives of the major international clones were present among the PNSP. The majority of serotypes and clones that showed penicillin-nonsusceptibility are present within the vaccine. Serotype switching was also noted to have occurred prior to introduction of the vaccine. This study provides a characterization of the pneumococcal serotypes associated with IPD and discharging ears that will be useful for detecting potential selective effects of the vaccine. This surveillance should be continued, as it will be important to monitor the frequency and distribution of serotypes in the post-vaccine era.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47057-0
2007-06-01
2024-10-11
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/6/819.html?itemId=/content/journal/jmm/10.1099/jmm.0.47057-0&mimeType=html&fmt=ahah

References

  1. Black S., Shinefield H. R. 2002; Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr 161:Suppl. 2S127–S132 [CrossRef]
    [Google Scholar]
  2. Clarke S. C., Scott K. J., McChlery S. M. 2004; Serotypes and sequence types of pneumococci causing invasive disease in Scotland prior to the introduction of pneumococcal conjugate polysaccharide vaccines. J Clin Microbiol 42:4449–4452 [CrossRef]
    [Google Scholar]
  3. Enright M. C., Spratt B. G. 1998; A multilocus sequence typing scheme for Streptococcus pneumoniae : identification of clones associated with serious invasive disease. Microbiology 144:3049–3060 [CrossRef]
    [Google Scholar]
  4. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., Takala A., Kayhty H., Karma P. other authors 2001; Efficacy of a pneumococcal conjugate vaccine against acute otitis media. Finnish Otitis Media Study Group.. N Engl J Med 344:403–409 [CrossRef]
    [Google Scholar]
  5. Gertz R. E., McEllistrem M. C., Boxrud D. J., Li Z., Sakota V., Thompson T. A., Facklam R. R., Besser J. M., Harrison L. H. other authors 2003; Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 41:4194–4216 [CrossRef]
    [Google Scholar]
  6. Hansman D., Bullen M. M. 1967; A resistant pneumococcus. Lancet 2:264–265
    [Google Scholar]
  7. Hogg G. G., Strachan J. E., Lester R. A. 2000; Invasive pneumococcal disease in the population of Victoria. Med J Aust 173, (Suppl.):S32–S35
    [Google Scholar]
  8. Jette L. P., Lamothe F. 1989; Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol 27:1–5
    [Google Scholar]
  9. Kertesz D. A., Di Fabio J. L., de Cunto Brandileone M. C., Castaneda E., Echaniz-Aviles G., Heitmann I., Homma A., Hortal M., Lovgren M. other authors 1998; Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study. PAHO Pneumococcal Surveillance Study Group. Clin Infect Dis 26:1355–1361 [CrossRef]
    [Google Scholar]
  10. McGee L., Klugman K. P., Wasas A., Capper T., Brink A. Antibiotics Surveillance Forum of South Africa 2001; Serotype 19F multiresistant pneumococcal clone harbouring two erythromycin resistance determinants [ erm (B) and mef (A)] in South Africa. Antimicrob Agents Chemother 45:1595–1598 [CrossRef]
    [Google Scholar]
  11. NCCLS 2003 Performance Standards for Antimicrobial Disk Susceptibility Test , 8th edn. Approved standard M2–A8 Wayne, PA: National Committee for Laboratory Standards;
    [Google Scholar]
  12. Nielsen S. V., Henrichsen J. 1992; Capsular types of Streptococcus pneumoniae isolated from blood and CSF during 1982–1987. Clin Infect Dis 15:794–798 [CrossRef]
    [Google Scholar]
  13. Pai R., Moore M. R., Pilishvili T., Gertz R. E., Whitney C. G., Beall B. Active Bacterial Core Surveillance Team; 2005; Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192:1988–1995 [CrossRef]
    [Google Scholar]
  14. Serrano I., Melo-Cristino J., Carriço J. A., Ramirez M. 2005; Characterization of the genetic lineages responsible for pneumococcal invasive disease in Portugal. J Clin Microbiol 43:1706–1715 [CrossRef]
    [Google Scholar]
  15. Shi Z. Y., Enright M. C., Wilkinson P., Griffiths D., Spratt B. G. 1998; Identification of the three major clones of multiply antibiotic-resistant Streptococcus pneumoniae in Taiwanese hospitals by multilocus sequencing typing. J Clin Microbiol 36:3514–3519
    [Google Scholar]
  16. Turnidge J. D., Bell J. M., Collignon P. J. 1999; Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Med J Aust 170:152–155
    [Google Scholar]
  17. van Belkum A., Sluijter M., de Groot R., Verbrugh H., Hermans P. W. M. 1996; Novel BOX repeat PCR assay for high-resolution typing of Streptococcus pneumoniae strains. J Clin Microbiol 34:1176–1179
    [Google Scholar]
  18. Watson M., Roche P., Bayley K., Bell J. M., Collignon P., Gilbert G. L., Hogg G., Keil A. D., Krause V. other authors 2004; Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program. Commun Dis Intell 28:455–464
    [Google Scholar]
  19. Whitney C. G., Farley M. M., Hadler J., Harrison L. H., Bennett N. M., Lynfield R., Reingold A., Cieslak P. R., Pilishvili T. other authors 2003; Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. Active Bacterial Core Surveillance of the Emerging Infections Program Network. N Engl J Med 348:1737–1746 [CrossRef]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.47057-0
Loading
/content/journal/jmm/10.1099/jmm.0.47057-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error